MedPath

?valuation of attenuation imaging (ATI) to elicit the degree of steatosis and shear wave dispersion mode (SWD) to quantify viscoelasticity in nonalcoholic steatohepatitis (NASH).

Conditions
K76.0
Fatty (change of) liver, not elsewhere classified
Registration Number
DRKS00029983
Lead Sponsor
Medizinische Klinik 1, Klinikum der Goethe-Universität
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
244
Inclusion Criteria

Signed informed consent from the patient or legal guardian; Substudy 1: patients with NASH/NAFLD; Substudy 2: patients with hepatologic disease (NASH/NAFLD, AIH, ASH, chronic hepatitis B infection, chronic hepatitis C infection) and existing histologic findings of the liver
Age 18 years.

Exclusion Criteria

Incapacitated patients, pregnancy or lactation, patients with advanced liver cirrhosis and decompensation

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Substudy 1: <br>AUC, sensitivity and specificity of the degree of steatosis determined by Attenuation Imaging (ATI) by comparing the measured values with results of a CAP measurement and with results of a liver biopsy (histologically determined NAFLD activity score (NAS) and the Steatosis, Activity and Fibrosis Score (SAS), respectively). <br><br>Substudy 2: <br>AUC, sensitivity, and specificity of viscoelasticity determined by SWD by correlation with histologically assessed inflammation grade. <br><br>Supplementary to Substudy 1 and 2:<br>AUC, sensitivity and specificity of elasticity determined by SWE by comparing results with Transient Elastography (Fibroscan®) readings.
Secondary Outcome Measures
NameTimeMethod
Influence of comorbidities on the diagnostic accuracy of the degree of steatosis and viscoelasticity (obesity (BMI), ascites).
© Copyright 2025. All Rights Reserved by MedPath